---
id: herpes-simplex-disseminated
condition: Disseminated Herpes Simplex Virus Infection
aliases: [disseminated HSV, HSV viremia, systemic herpes simplex]
icd10: [B00.7, B00.89]
esi: 2
time_to_harm: "< 24 hours (fulminant hepatitis, encephalitis); < 72 hours (multi-organ failure)"
category: infectious
track: tier1
sources:
  - type: guideline
    ref: "NIH Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Herpes Simplex Virus, 2024"
  - type: guideline
    ref: "CDC STI Treatment Guidelines: Herpes, 2021"
  - type: review
    ref: "Acyclovir. StatPearls, NCBI Bookshelf, 2024"
last_updated: "2026-03-01"
compiled_by: agent
risk_tier: A
validation:
  automated_consistency_check: null
  dose_range_validator: null
  unit_normalization_check: null
  cross_file_consistency_check: null
  citation_presence_check: null
  duplicate_content_check: null
  outlier_detection_flag: clear
  schema_version: "2.0"
  provenance_links: []
---
# Disseminated Herpes Simplex Virus Infection

## Recognition

**Presentation:**
- Widespread vesicular or ulcerative lesions beyond typical dermatome/mucosal distribution
- Fever, malaise, myalgias
- Hepatitis: Rapidly rising transaminases (ALT/AST often > 1000), coagulopathy, jaundice
- Encephalitis: Altered mental status, seizures, focal neurologic deficits (temporal lobe predilection)
- Pneumonitis: Dyspnea, cough, bilateral infiltrates
- Disseminated intravascular coagulation (DIC)

**High-risk populations:**
- Neonates (peripartum transmission)
- Immunocompromised (HIV/AIDS, transplant recipients, chemotherapy)
- Pregnancy (especially third trimester — HSV hepatitis)
- Burns patients, eczema herpeticum
- Occasionally immunocompetent individuals

**Organs involved in dissemination:**
- Liver (HSV hepatitis — 25% mortality)
- CNS (encephalitis — 70% mortality untreated)
- Lungs (pneumonitis)
- Adrenal glands
- Bone marrow
- GI tract (esophagitis, colitis)

## Critical Actions

1. **Start IV acyclovir immediately** if disseminated HSV suspected — do NOT wait for confirmatory testing
2. **Acyclovir 10 mg/kg IV q8h** infused over 1 hour — begin within 1 hour of suspicion
3. **Assess for encephalitis** — altered mental status, seizures, or focal deficits require emergent LP and MRI brain
4. **Check hepatic panel** — anicteric hepatitis with massively elevated transaminases is characteristic
5. **Assess for DIC** — fibrinogen, D-dimer, PT/INR, platelet count
6. **Aggressive IV hydration** — acyclovir is nephrotoxic; maintain urine output > 1 mL/kg/hr

## Differential Diagnosis

- Varicella-zoster virus (VZV) dissemination — dermatomal distribution initially, older patients
- Disseminated gonococcemia — pustular lesions, tenosynovitis, arthralgias
- Secondary syphilis — non-vesicular rash, mucous patches, condylomata
- Enteroviral infection — exanthem, myocarditis
- Drug reaction (SJS/TEN) — mucosal involvement, Nikolsky sign, drug exposure history
- Acute hepatitis (viral, autoimmune, drug) — if hepatitis dominates presentation
- Meningococcemia — purpuric lesions, rapid hemodynamic collapse

## Workup

- **HSV PCR** (blood, CSF, lesion swab) — most sensitive and specific test
- **Direct fluorescent antibody (DFA)** from lesion scraping — rapid but less sensitive
- **Tzanck smear** — multinucleated giant cells; low sensitivity, cannot distinguish HSV from VZV
- **Liver panel** — markedly elevated AST/ALT (often > 5000 IU/L in HSV hepatitis), low bilirubin early
- **Coagulation studies** — PT/INR, fibrinogen, D-dimer for DIC
- **CBC with differential** — leukopenia or leukocytosis, thrombocytopenia
- **BMP** — renal function (baseline for acyclovir dosing)
- **Lumbar puncture** if encephalitis suspected — lymphocytic pleocytosis, elevated protein, RBCs; HSV PCR of CSF
- **MRI brain with contrast** — temporal lobe signal abnormality in HSV encephalitis
- **CXR or CT chest** if pneumonitis suspected
- **Liver biopsy** may be needed if hepatitis etiology unclear (but often too coagulopathic)

## Treatment

### Antiviral Therapy
- **Acyclovir 10 mg/kg IV q8h** (based on ideal body weight)
- Infuse each dose over minimum 1 hour to prevent crystalline nephropathy
- **Duration:** Minimum 14-21 days for disseminated disease; 21 days for encephalitis
- **Renal dose adjustment required:** CrCl 25-50: 10 mg/kg q12h; CrCl 10-25: 10 mg/kg q24h

### For Acyclovir-Resistant HSV (Immunocompromised)
- **Foscarnet 40 mg/kg IV q8h** (or 60 mg/kg IV q12h)
- Foscarnet is highly nephrotoxic — aggressive hydration, monitor electrolytes (Ca, Mg, K, PO4)

### Supportive Care
- IV crystalloid resuscitation — maintain UOP > 1 mL/kg/hr
- Correct coagulopathy: FFP 15 mL/kg if active bleeding, cryoprecipitate if fibrinogen < 150 mg/dL
- Antiepileptic prophylaxis NOT indicated unless seizures occur
- N-acetylcysteine may be considered in fulminant HSV hepatitis (by analogy with other causes of ALF)

### Liver Transplant Consideration
- HSV hepatitis with fulminant liver failure: contact transplant hepatology early

## Disposition

- **All patients:** ICU admission for disseminated HSV
- **Encephalitis:** Neurology and neurosurgery consultation; continuous EEG monitoring if seizures
- **Fulminant hepatitis:** Transplant hepatology consultation; King's College criteria for transplant listing
- **Isolation:** Contact precautions for skin lesions; add airborne if pneumonitis
- **Reportable:** Not routinely reportable; neonatal HSV may be reportable in some jurisdictions

## Pitfalls

1. **Failing to consider disseminated HSV in the pregnant patient with anicteric hepatitis.** Pregnant women in the third trimester with fever and massively elevated transaminases should receive empiric IV acyclovir pending workup. Delay is frequently fatal.

2. **Waiting for PCR results before starting acyclovir.** Disseminated HSV is a clinical diagnosis requiring empiric treatment. PCR takes 24-48 hours; mortality increases with every hour of delay.

3. **Inadequate hydration during acyclovir infusion.** Acyclovir precipitates in renal tubules. Bolus 500-1000 mL NS before infusion and maintain high urine output throughout treatment.

4. **Missing HSV encephalitis.** Temporal lobe symptoms (personality change, olfactory hallucinations, aphasia, seizures) in a febrile patient mandate LP and MRI. Normal early CT does not exclude encephalitis.

5. **Assuming HSV only affects immunocompromised patients.** Disseminated HSV can occur in immunocompetent individuals, especially neonates and pregnant women.

6. **Not checking for DIC.** Disseminated HSV commonly triggers DIC. Early recognition and treatment of coagulopathy is life-saving.
